ADAPTIMMUNE THERAPEUTICS PLC Selling, General and Administrative Expense
ADAPTIMMUNE THERAPEUTICS PLC (ADAPY) reported Selling, General and Administrative Expense of $18.48 million for the 3-month period ending 2025-06-30, per its 10-Q filed 2025-08-13.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:SellingGeneralAndAdministrativeExpense · last filed 2025-08-13
- ADAPTIMMUNE THERAPEUTICS PLC selling, general and administrative expense for the quarter ending 2025-06-30 was $18.48M, a 3.13% decline year-over-year.
- ADAPTIMMUNE THERAPEUTICS PLC selling, general and administrative expense for the quarter ending 2025-03-31 was $23.28M, a 17.99% increase year-over-year.
- ADAPTIMMUNE THERAPEUTICS PLC selling, general and administrative expense for the quarter ending 2024-12-31 was $27.17M, a 60.96% increase year-over-year.
- ADAPTIMMUNE THERAPEUTICS PLC selling, general and administrative expense for the quarter ending 2024-09-30 was $21.28M, a 31.63% increase year-over-year.
- ADAPTIMMUNE THERAPEUTICS PLC selling, general and administrative expense for fiscal 2024 was $87.26M, a 18.70% increase from fiscal 2023.
- ADAPTIMMUNE THERAPEUTICS PLC selling, general and administrative expense for fiscal 2023 was $73.51M, a 15.97% increase from fiscal 2022.
- ADAPTIMMUNE THERAPEUTICS PLC selling, general and administrative expense for fiscal 2022 was $63.39M.
| Period end | Selling, General and Administrative Expense 3 month | Selling, General and Administrative Expense 6 month | Selling, General and Administrative Expense 9 month | Selling, General and Administrative Expense 12 month |
|---|---|---|---|---|
| 2025-06-30 | $18.48M 10-Q · filed 2025-08-13 | $41.77M 10-Q · filed 2025-08-13 | $68.94M derived: sum of 3 quarters · filed 2025-08-13 | $90.21M derived: sum of 4 quarters · filed 2025-08-13 |
| 2025-03-31 | $23.28M 10-Q · filed 2025-05-13 | $50.45M derived: sum of 2 quarters · filed 2025-05-13 | $71.73M derived: sum of 3 quarters · filed 2025-05-13 | $90.81M derived: sum of 4 quarters · filed 2025-08-13 |
| 2024-12-31 | $27.17M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-24 | $48.45M derived: sum of 2 quarters · filed 2025-03-24 | $67.53M derived: sum of 3 quarters · filed 2025-08-13 | $87.26M 10-K · filed 2025-03-24 |
| 2024-09-30 | $21.28M 10-Q · filed 2024-11-13 | $40.36M derived: sum of 2 quarters · filed 2025-08-13 | $60.09M 10-Q · filed 2024-11-13 | $76.97M derived: sum of 4 quarters · filed 2025-08-13 |
| 2024-06-30 | $19.08M 10-Q · filed 2025-08-13 | $38.81M 10-Q · filed 2025-08-13 | $55.69M derived: sum of 3 quarters · filed 2025-08-13 | $71.86M derived: sum of 4 quarters · filed 2025-08-13 |
| 2024-03-31 | $19.73M 10-Q · filed 2025-05-13 | $36.61M derived: sum of 2 quarters · filed 2025-05-13 | $52.77M derived: sum of 3 quarters · filed 2025-05-13 | |
| 2023-12-31 | $16.88M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-24 | $33.04M derived: sum of 2 quarters · filed 2025-03-24 | $73.51M 10-K · filed 2025-03-24 | |
| 2023-09-30 | $16.16M 10-Q · filed 2024-11-13 | $56.63M 10-Q · filed 2024-11-13 | ||
| 2022-12-31 | $63.39M 10-K · filed 2025-03-24 |